Sugi Predict

Sugi Predict / Compounds / Dynasore

Dynasore

Dynasore

SCHEMBL847982

O=C(NN=Cc1ccc(O)c(O)c1)c1cc2ccccc2cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DNM1 Q05193 3/20 1.00
▸ ECE2 P0DPD6 2/20 1.00
▸ ECE1 P42892 2/20 1.00
▸ MUS81 Q96NY9 2/20 1.00
▸ NTRK1 P04629 1/20 0.73
▸ L3MBTL1 Q9Y468 1/20 0.73
▸ AR P10275 2/20 0.69
▸ MEN1 O00255 5/20 0.66
▸ KMT2A Q03164 5/20 0.66
▸ PGR P06401 1/20 0.64
▸ GAA P10253 2/20 0.62
▸ MGAM O43451 1/20 0.62
▸ SI P14410 1/20 0.62
▸ MGAM2 Q2M2H8 1/20 0.62
▸ POLB P06746 2/20 0.60
▸ NOX4 Q9NPH5 1/20 0.60
▸ ALPL P05186 1/20 0.60
▸ ALPI P09923 1/20 0.60
▸ ALPG P10696 1/20 0.60
▸ BLM P54132 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dynasore SCHEMBL16342920 1.00 DNM1 (1.00) DNM1ECE2ECE1MUS81NTRK1
Dynasore SCHEMBL30917221 1.00 DNM1 (1.00) DNM1ECE2ECE1MUS81NTRK1
Dynasore SCHEMBL4570231 1.00 DNM1 (1.00) DNM1ECE2ECE1MUS81NTRK1
Dynasore SCHEMBL29695524 1.00 DNM1 (1.00) DNM1ECE2ECE1MUS81NTRK1
Dynasore SCHEMBL30961945 1.00 DNM1 (1.00) DNM1ECE2ECE1MUS81NTRK1
Dynasore SCHEMBL29385895 1.00 DNM1 (1.00) DNM1ECE2ECE1MUS81NTRK1
Dynasore SCHEMBL29435816 0.99 DNM1 (0.97) DNM1ECE2ECE1MUS81NTRK1
SCHEMBL14983909 0.90 DNM1 (0.82) DNM1ECE2ECE1MUS81NTRK1
SCHEMBL25474226 0.88 DNM1 (0.79) DNM1ECE2ECE1MUS81NTRK1
SCHEMBL18876543 0.88 DNM1 (0.79) DNM1ECE2ECE1MUS81NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10960020-B2 Modulation of PCSK9 and LDLR through DRP1 inhibition THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2021-03-30 — — US claimed
US-20180298057-A1 Compositions and Methods for Managing Respiratory Conditions UNIV EMORY (US) 2018-10-18 — — US claimed
US-10960020-B2 Modulation of PCSK9 and LDLR through DRP1 inhibition THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2021-03-30 — — US disclosed
US-10919934-B2 Compositions and methods for managing respiratory conditions EMORY UNIVERSITY (US) 2021-02-16 — — US disclosed
US-20200331965-A1 Compositions and Methods for Managing Respiratory Conditions UNIV EMORY (US) 2020-10-22 — — US disclosed
US-10738079-B2 Compositions and methods for managing respiratory conditions EMORY UNIVERSITY (US) 2020-08-11 — — US disclosed
US-20190209603-A1 MODULATION OF PCSK9 AND LDLR THROUGH DRP1 INHIBITION THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2019-07-11 — — US disclosed
US-20180298057-A1 Compositions and Methods for Managing Respiratory Conditions UNIV EMORY (US) 2018-10-18 — — US disclosed
EP-3045912-B1 A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL UMC UTRECHT HOLDING BV (NL) 2018-09-19 — — EP disclosed
US-10006904-B2 Rapid quantitative assay to measure CFTR function in a primary intestinal culture model UMC UTRECHT HOLDING B.V. (NL) 2018-06-26 — — US disclosed
EP-3045912-A1 A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL UMC Utrecht Holding B.V. (NL) 2016-07-20 — — EP disclosed
EP-2795322-B1 A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL UMC UTRECHT HOLDING BV (NL) 2015-12-09 — — EP disclosed
US-20150276719-A2 A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL UMC UTRECHT HOLDING B.V. (NL) 2015-10-01 — — US disclosed
US-20150011420-A1 RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL UMC UTRECHT HOLDING B.V. (NL) 2015-01-08 — — US disclosed
EP-2432465-A1 USE OF DYNAMIN RING STABILIZERS Children's Medical Research Institute (AU) 2012-03-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738079-B2 Compositions and methods for managing respiratory conditions EPCAM, ANXA5, CFTR DNM1 1540/4885ECE2 537/4885ECE1 447/4885
US-10960020-B2 Modulation of PCSK9 and LDLR through DRP1 inhibition LDLR, PCSK9, DNM1L DNM1 6/4885ECE2 593/4885ECE1 363/4885
US-10919934-B2 Compositions and methods for managing respiratory conditions EPCAM, ANXA5, CFTR DNM1 1540/4885ECE2 537/4885ECE1 447/4885
US-20180298057-A1 Compositions and Methods for Managing Respiratory Conditions EPCAM, ANXA5, CFTR DNM1 1540/4885ECE2 537/4885ECE1 447/4885
US-20200331965-A1 Compositions and Methods for Managing Respiratory Conditions EPCAM, ANXA5, CFTR DNM1 1540/4885ECE2 537/4885ECE1 447/4885
US-20190209603-A1 MODULATION OF PCSK9 AND LDLR THROUGH DRP1 INHIBITION LDLR, PCSK9, DNM1L DNM1 6/4885ECE2 593/4885ECE1 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.